ONC201 shows promise in AML treatment

被引：7

作者：

Edwards, Holly ^{[1
,2
]}

Ge, Yubin ^{[1
,2
,3
]}

机构：

[1] Wayne State Univ, Sch Med, Dept Oncol, 421 E Canfield, Detroit, MI 48201 USA

[2] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI USA

[3] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA

来源：

CELL CYCLE | 2018年 / 17卷 / 03期

关键词：

ONC201; leukemia; imipridone; TRAIL; LEUKEMIA;

D O I：

10.1080/15384101.2017.1421035

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

引用

页码：277 / 277

页数：1

共 7 条

[1] Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects [J].

Allen, Joshua E. ;

Krigsfeld, Gabriel ;

Mayes, Patrick A. ;

Patel, Luv ;

Dicker, David T. ;

Patel, Akshal S. ;

Dolloff, Nathan G. ;

Messaris, Evangelos ;

Scata, Kimberly A. ;

Wang, Wenge ;

Zhou, Jun-Ying ;

Wu, Gen Sheng ;

El-Deiry, Wafik S. .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (171)

[2] A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma [J].

Arrillaga-Romany, Isabel ;

Chi, Andrew S. ;

Allen, Joshua E. ;

Oster, Wolfgang ;

Wen, Patrick Y. ;

Batchelor, Tracy T. .

ONCOTARGET, 2017, 8 (45) :79298-79304

[3] Treatment of Relapsed/Refractory Acute Myeloid Leukemia [J].

Bose, Prithviraj ;

Vachhani, Pankit ;

Cortes, Jorge E. .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (03)

[4] Evolution of acute myelogenous leukemia stem cell properties after treatment and progression [J].

Ho, Tzu-Chieh ;

LaMere, Mark ;

Stevens, Brett M. ;

Ashton, John M. ;

Myers, Jason R. ;

O'Dwyer, Kristen M. ;

Liesveld, Jane L. ;

Mendler, Jason H. ;

Guzman, Monica ;

Morrissette, Jennifer D. ;

Zhao, Jianhua ;

Wang, Eunice S. ;

Wetzler, Meir ;

Jordan, Craig T. ;

Becker, Michael W. .

BLOOD, 2016, 128 (13) :1671-1678

[5] ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies [J].

Ishizawa, Jo ;

Kojima, Kensuke ;

Chachad, Dhruv ;

Ruvolo, Peter ;

Ruvolo, Vivian ;

Jacamo, Rodrigo O. ;

Borthakur, Gautam ;

Mu, Hong ;

Zeng, Zhihong ;

Tabe, Yoko ;

Allen, Joshua E. ;

Wang, Zhiqiang ;

Ma, Wencai ;

Lee, Hans C. ;

Orlowski, Robert ;

Sarbassov, Dos D. ;

Lorenzi, Philip L. ;

Huang, Xuelin ;

Neelapu, Sattva S. ;

McDonnell, Timothy ;

Miranda, Roberto N. ;

Wang, Michael ;

Kantarjian, Hagop ;

Konopleva, Marina ;

Davis, R. Eric ;

Andreeff, Michael .

SCIENCE SIGNALING, 2016, 9 (415)

[6] Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies [J].

Prabhu, Varun V. ;

Talekar, Mala K. ;

Lulla, Amriti R. ;

Kline, C. Leah B. ;

Zhou, Lanlan ;

Hall, Junior ;

Van den Heuvel, A. Pieter J. ;

Dicker, David T. ;

Babar, Jawad ;

Grupp, Stephan A. ;

Garnett, Mathew J. ;

McDermott, Ultan ;

Benes, Cyril H. ;

Pu, Jeffrey J. ;

Claxton, David F. ;

Khan, Nadia ;

Oster, Wolfgang ;

Allen, Joshua E. ;

El-Deiry, Wafik S. .

CELL CYCLE, 2018, 17 (04) :468-478

[7] First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors [J].

Stein, Mark N. ;

Bertino, Joseph R. ;

Kaufman, Howard L. ;

Mayer, Tina ;

Moss, Rebecca ;

Silk, Ann ;

Chan, Nancy ;

Malhotra, Jyoti ;

Rodriguez, Lorna ;

Aisner, Joseph ;

Aiken, Robert D. ;

Haffty, Bruce G. ;

DiPaola, Robert S. ;

Saunders, Tracie ;

Zloza, Andrew ;

Damare, Sherri ;

Beckett, Yasmeen ;

Yu, Bangning ;

Najmi, Saltanat ;

Gabel, Christian ;

Dickerson, Siobhan ;

Zheng, Ling ;

El-Deiry, Wafik S. ;

Allen, Joshua E. ;

Stogniew, Martin ;

Oster, Wolfgang ;

Mehnert, Janice M. .

CLINICAL CANCER RESEARCH, 2017, 23 (15) :4163-4169

← 1 →